Pharmacotherapy of essential thrombocythaemia: economic considerations

Bibliography

• RIDELL B, CARNESKOG J, WEDEL H et al.: Incidence of chronic myeloproliferative disorders in the city of Goteborg, Sweden 1983-1992. Eur: Hematol (2000) 65:267–271.
   PubMed Web of Science ®Google Scholar
• ROZMAN C, GIRALT M, FELIU E et al.: Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer (1991) 67:2658–2663.
   PubMed Web of Science ®Google Scholar
• TEFFERI A, MURPHY S: Current option in essential thrombocythemia: pathogenesis, diagnosis and management. Blood reviews (2001) 15:121–131.
   PubMed Web of Science ®Google Scholar
• TEFFERI A, SOLBERG LA, SILVERSTEIN MN: A clinical update in polycythemia vera and essential thrombocythemia. Am. Med. (2000) 109:141–149.
   PubMed Web of Science ®Google Scholar
• RUGGERI M, FINAZZI G, TOSETTO Aet al.: No treatment for low-risk thrombocythaemia: results from a prospective study. Br. Haematol (1998) 103:772–777.
   Google Scholar
• MICHIELS JJ, VAN GENDEREN PJJ, LINDEMANS J, VAN VLIET HHDM: Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia. Leak. Lymphoma (1996) 22\(Suppl. 1):47–56.
   Google Scholar
• PEARSON TC: The risk of thrombosis in essential thrombocythemia and polycythemia vera. Semin. Oncol (2002) 29:16–21.
   PubMed Web of Science ®Google Scholar
• GENDEREN VAN PJJ, BUDDE U, MICHIELS JJ et al.: The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. Br. Haematol (1996) 93:962–965.
   PubMedGoogle Scholar
• BESSES C, CERVANTES F, PEREIRA Aet al.: Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia (1999) 13:150–154.
   Google Scholar
• CORTELAZZO S, VIERO P, FINAZZI G et al.: Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. ./. Clin. Omni (1990) 8:556–562.
   PubMed Web of Science ®Google Scholar
• COLOMBI M, RADAELLI F, ZOCCHI L, MAIOLO AT: Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer (1991) 67:2926–2930.
   Google Scholar
• JANTUNEN R, JUVONEN E, IKKALA E et al.: The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia. Ann. Hematol (2001) 80:74–78.
   PubMed Web of Science ®Google Scholar
• BELLUCCI S, JAN VIER M, TOBELEM G et al.: Essential thrombocythemias: clinical evolutionary and biological data. Cancer (1986) 58:2440–2447.
   PubMed Web of Science ®Google Scholar
• FENAUX P, SIMON M, CAULIER MT et al.: Clinical course of essential thrombocythemia in 147 cases. Cancer (1990) 66:549–556.
   PubMed Web of Science ®Google Scholar
• LAHUERTA-PALACIOS JJL, BORNSTEIN R, FERNANDEZ-DEBORA FJ et al: Controlled and uncontrolled thrombocytosis. Its clinical role in thrombocythemia. Cancer (1988) 61:1207–1212.
   Google Scholar
• PEARSON TC, BAREFORD D, CRAIG Jet al.: The management of low-risk and intermediate-risk patients with primary thrombocythaemia. Br. Haematol (1999) 106:833.
   Google Scholar
• BARBUI T, FINAZZI G: Clinical parameters for determing when and when not to treat essential thrombocythemia. Semin. Hematol (1999) 36\(Suppl. 2):14–18.
   Google Scholar
• GRIESSHAMMER M, BERGMANN L, HAFNER M et al.: Treatment and clinical course of essential thrombocythemia (ET): preliminary results of a prospective multicenter trial. Blood (1998) 92\(Suppl. 1):423a (Abstract 1750).
   Google Scholar
• CORTELAZZO S, FINAZZI G, RUGGERI M et al.: Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl. Med. (1995) 332:1132–1136.
   PubMed Web of Science ®Google Scholar
• WEINFELD A, SWOLIN B, WESTIN J: Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur: Haematol (1994) 52:134–139.
   PubMed Web of Science ®Google Scholar
• NAND S, STOCK W, GODWIN J, FISHER SG: Leukemogenic risk of hydroxyurea therapy in polycythaemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Am. Hematol (1996) 52:42–46.
   PubMed Web of Science ®Google Scholar
• STERKERS Y, PREUDHOMME C, LAI JL et al.: Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood (1998) 91:616–622.
   PubMed Web of Science ®Google Scholar
• MURPHY S, PETERSON P, ILAND H, LASZLO J: Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival and leukemic transition by treatment. Semin. Hematol (1997) 34:29–39.
   PubMed Web of Science ®Google Scholar
• FINAZZI G, RUGGERI M, RODEGHIERO F, BARBUI T: Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clincial trial. Br. J. Haematol (2000) 110:577–583.
   PubMed Web of Science ®Google Scholar
• HANFT VN, FRUCHTMAN SR, PICKENS CV et al.: Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood (2000) 95:3589–3593.
   PubMed Web of Science ®Google Scholar
• FINAZZI G, RUGGERI M, RODEGHIERO F, BARBUI T: Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood (2003) 101:3749.
   PubMed Web of Science ®Google Scholar
• PASSAMONTI F, MALABARBA L, ORLANDI E et al: Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. Br. Haematol (2002) 116:855–861.
   PubMed Web of Science ®Google Scholar
• KILADJIAN JJ, GARDIN C, RENOUX M et al.: Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. Hematol (2003) 4:198–207.
   Google Scholar
• LENGFELDER E, GRIESSHAMMER M, HEHLMANN R: Interferon-alpha in the treatment of essential thrombocythemia. Leak. Lymhoma (1996) 22\(Suppl. 1):135–142.
   Google Scholar
• ELLIOT MA, TEFFERI A: Interferon-a therapy in polycythaemia vera and essential thrombocythemia. Sem. Thromb. Hemost. (1997) 23:463–472.
   PubMed Web of Science ®Google Scholar
• GILBERT HS: Long term treatment of myeloproliferative disease with Interferon-alpha-2b: feasability and efficacy. Cancer (1998) 83:1205–1213.
   PubMed Web of Science ®Google Scholar
• BENTLEY M, TAYLOR K, GRIGG A et al.: Long-term interferon-alpha-2a does not induce sustained hematologic remission in younger patients with essential thrombocythemia. Leak. Lymphoma (1999) 36:123–128.
   PubMed Web of Science ®Google Scholar
• ALVARADO Y, CORTES J, VERSTOVSEK S et al.: Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother. Pharmacol (2003) 51:81–86.
   PubMed Web of Science ®Google Scholar
• TOMER A: Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood (2002) 99:1602–1609.
   PubMed Web of Science ®Google Scholar
• STOREN EC, TEFFERI A: Long-term useof anagrelide in young patients with essential thrombocythemia. Blood (2001) 97:863–866.
   PubMed Web of Science ®Google Scholar
• GRIESSHAMMER M, BANGERTER M, VAN VLIET HH, MICHIELS JJ: Aspirin in essential thrombocythemia: status quo and quo vadis. Semin. Thromb. Hemost. (1997) 23:371–377.
   PubMed Web of Science ®Google Scholar
• ROCCA B, CIABATTONI G, TARTAGLIONE R et al.: Increased thromboxane biosynthesis in essential thrombocythemia. Thromb. Haemost. (1995) 74:1225–1230.
   PubMed Web of Science ®Google Scholar
• GENDEREN VAN PJJ, MULDER PGH, WALEBOER M et al.: Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br. J. Haematol (1997) 97:179–184.
   PubMed Web of Science ®Google Scholar
• GENDEREN VAN PJJ, PRINS FJ, MICHIELS JJ et al.: Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: a rationale for the use of low-dose aspirin as an antithrombotic agent. Br: J. Haematol (1999) 104:438–441.
   PubMed Web of Science ®Google Scholar
• MAGEN-NATIV H, STARK P, KADOSH S et al: Hemostatic complications and role of aspirin in myeloproliferative disorders: result of long term follow-up of 394 patients. Haematol (2000) 1\(Supp1.1):75 (Abstract).
   Google Scholar
• THIELE J, KVASNICKA HM: Chronicmyeloproliferative disorders. The new WHO classification. Pathologe (2001) 22:429–443.
   Google Scholar
• GOLUB R, ADAMS J, DAVE S, BENNETT CL: Cost-effectiveness considerations in the treatment of essential thrombocythemia. Semin. Oncol (2000) 29:28–32.
   Web of Science ®Google Scholar
• BENNETT CL, WEINBERG PO, GOLUB RM: Cost-effectiveness model of a phase II clinical trial of a new pharmaceutical for essential thrombocythemia: is it helpful to policy makers? Semin. Hematol (1999) 36:26–29.
   Web of Science ®Google Scholar
• Anagrelide project #29Z: integrated summary of efficacy (final report), Roberts Pharmaceuticals, Eatontown, NJ, USA (1995).
   Google Scholar